Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316108 · ClinicalTrials.gov registry record · NA
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 747
- Enrollment target
NCT00316108 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 747 participants.
The verdict
NCT00316108, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 747 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be less than or equal to that of objective performance criteria (OPC) derived from historic controls undergoing surgical intervention with a carotid endarterectomy (CEA).
Interventions
- DEVICE WALLSTENT® Endoprosthesis™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2002-02 |
| Est. Completion | 2007-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316108
The ClinicalTrials.gov registry entry for NCT00316108 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WALLSTENT® Endoprosthesis™ is the first listed.
NCT00316108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316108 about?
NCT00316108 is a clinical study titled "Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)". The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be less than or equal to that of objective performance criteria (OPC) derived...
What is the current status of trial NCT00316108?
This trial is currently completed. It is a NA study. The enrollment target is 747 participants. The study started on 2002-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00316108?
The interventions under investigation include: WALLSTENT® Endoprosthesis™ (DEVICE).
Who is sponsoring clinical trial NCT00316108?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.